SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
OXiGENE to Present Data Showing Importance of Local Site Pathology Confirmation in Phase 2/3 Clinical Trial of Zybrestat® in Anaplastic Thyroid Cancer